Literature DB >> 7506196

The pharmacokinetic profile of nimesulide in healthy volunteers.

A Bernareggi1.   

Abstract

After oral administration of nimesulide 100mg in tablet, granule or suspension to healthy volunteers, the drug was rapidly and extensively absorbed. Mean peak plasma concentrations of 2.86 to 4.58 mg/L were achieved within 1.22 to 3.83 hours of administration. The presence of food did not reduce either the rate or the extent of nimesulide absorption. When administered in suppository form, nimesulide peak plasma concentrations were lower and occurred later than those achieved after oral administration; the bioavailability of nimesulide given by suppository ranged from 54 to 96%, relative to that of orally administered formulations. Nimesulide is rapidly distributed, principally throughout the extracellular fluid compartment; values for volume of distribution ranged from 0.19 to 0.39 L/kg. Nimesulide is extensively bound to plasma proteins: at concentrations ranging from 0.5 to 10 mg/L, the unbound fraction varied between 0.7 and 4.0%. With oral administration, nimesulide concentrations decline monoexponentially following peak levels. The estimated mean terminal half-life for nimesulide varied from 1.96 to 4.73 hours. Excretion of unchanged drug in urine and faeces is negligible. Nimesulide is mainly eliminated by metabolic transformation and the principal metabolite is the 4'-hydroxy derivative. The presence of other metabolites is being evaluated. Excretion of nimesulide metabolites in the urine and faeces accounts for about 80 and 20% of the administered dose, respectively. Total plasma clearance of nimesulide was 39.7 to 90.9 ml/h/kg, reflecting almost exclusive metabolic clearance. The drug has a low extraction ratio, close to 0.1. Differences in gender have only a limited influence on the pharmacokinetic profile of nimesulide and its hydroxylated metabolite. With twice-daily administration of nimesulide 100 mg (tablets) or 200mg (suppositories), steady-state is achieved within 24 to 36 hours (2 to 3 administrations). With oral nimesulide 100mg twice daily, only modest accumulation of nimesulide and its 4'-hydroxy derivative occurs (Rmin, 1.59 for nimesulide and 1.46 for the hydroxylated metabolite).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7506196     DOI: 10.2165/00003495-199300461-00013

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  4 in total

1.  First dose and steady state pharmacokinetics of nimesulide and its 4-hydroxy metabolite in healthy volunteers.

Authors:  R Gandini; C Montalto; D Castoldi; V Monzani; M L Nava; I Scaricabarozzi; G Vargiu; I Bartosek
Journal:  Farmaco       Date:  1991-09

2.  [Comparison of the bioavailability of 2 different equal-dosage oral pharmaceutic forms of nimesulide in healthy volunteers].

Authors:  A Alessandrini; E Ballarin; A Bastianon; C Migliavacca
Journal:  Clin Ter       Date:  1986-08-15

3.  Simultaneous determination of nimesulide and hydroxynimesulide in human plasma and urine by high-performance liquid chromatography.

Authors:  D Castoldi; V Monzani; O Tofanetti
Journal:  J Chromatogr       Date:  1988-03-18

Review 4.  Nimesulide. A preliminary review of its pharmacological properties and therapeutic efficacy in inflammation and pain states.

Authors:  A Ward; R N Brogden
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

  4 in total
  7 in total

Review 1.  Drug monitoring in nonconventional biological fluids and matrices.

Authors:  S Pichini; I Altieri; P Zuccaro; R Pacifici
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

2.  Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs.

Authors:  F Giuliano; T D Warner
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

Review 3.  Gender effects in pharmacokinetics and pharmacodynamics.

Authors:  R Z Harris; L Z Benet; J B Schwartz
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of nimesulide.

Authors:  A Bernareggi
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

Review 5.  Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  R Davis; R N Brogden
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

Review 6.  Non-Steroidal Anti-Inflammatory Drugs and Brain Inflammation: Effects on Microglial Functions.

Authors:  Maria Antonietta Ajmone-Cat; Antonietta Bernardo; Anita Greco; Luisa Minghetti
Journal:  Pharmaceuticals (Basel)       Date:  2010-06-14

Review 7.  NSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen Species.

Authors:  Rajeshwary Ghosh; Azra Alajbegovic; Aldrin V Gomes
Journal:  Oxid Med Cell Longev       Date:  2015-09-20       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.